DOPG Nanovesicles Blocking pHsp70-Driven Tumor Immunosuppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Tumor cells communicate with the tumor microenvironment (TME) to induce immunosuppression, hindering effective immune responses against cancer growth, necessitating disruption of this signaling pathway to enhance therapeutic efficacy.

Innovation Solution

Administering lipid nanovesicles composed of dioleoylphosphatidylglycerol (DOPG) and optionally saposin C (SapC) to inhibit the immunosuppressive pathway by blocking the action of phosphorylated heat shock protein 70 (pHsp70) on toll-like receptors (TLRs), thereby reducing M2 macrophage polarization and promoting M1 polarization in the TME.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If tumor cells communicate with the tumor microenvironment to induce immunosuppression, then tumor growth is promoted, but immune response effectiveness is reduced

Engineering Contradiction:

Improvetumor growth rateVSAvoidimmune response effectiveness

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent uses lipid nanovesicles as intermediary carriers to deliver immunomodulatory compounds (such as CpG oligonucleotides, cytokines, or other immune-stimulating agents) to the tumor microenvironment. These nanovesicles mediate the interaction between the therapeutic agent and the TME, disrupting the immunosuppressive signaling pathway while enhancing immune response. The nanovesicle acts as a bridge that converts the harmful tumor-TME communication into a beneficial immune-stimulating signal.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent alters the chemical and physical parameters of the tumor microenvironment by introducing nanovesicles with specific lipid compositions (e.g., cationic lipids, PEGylated lipids) that change the local immunological parameters. This includes modifying the charge, size, and surface properties of particles in the TME to shift the balance from immunosuppression to immune activation, thereby changing the functional state of immune cells in the microenvironment.

Inventive Principle:

Principle #35Parameter changes

2Object-generated harmful factors

If M2 macrophage polarization is enhanced in the tumor microenvironment, then immunosuppression is increased, but M1 macrophage polarization is reduced

Engineering Contradiction:

Improveimmunosuppression levelVSAvoidanti-tumor immune response

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent inverts the macrophage polarization pathway by delivering therapeutic agents through nanovesicles that specifically target and reprogram M2 macrophages into M1 phenotype, or directly stimulate M1 polarization. Instead of allowing the natural progression toward M2 immunosuppressive polarization, the treatment reverses this process by introducing signals that promote M1 anti-tumor macrophage differentiation, thereby converting harmful M2 cells into beneficial M1 cells.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent changes the polarization state of macrophages by altering key parameters such as cytokine profiles, epigenetic markers, and surface receptor expression. The nanovesicle-delivered therapeutics modify the chemical environment and signaling parameters within the TME to shift macrophage differentiation toward the M1 phenotype, characterized by increased iNOS expression, pro-inflammatory cytokine production, and enhanced tumor cell killing activity.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If conventional chemotherapy is administered, then tumor cell proliferation is inhibited, but immunosuppression in the TME persists

Engineering Contradiction:

Improvetumor cell proliferation rateVSAvoidimmunosuppression

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent merges conventional chemotherapy with immunomodulatory therapy by co-delivering chemotherapeutic agents and immune-stimulating compounds within the same nanovesicle system. This combination approach allows simultaneous inhibition of tumor cell proliferation (via chemotherapy) and disruption of immunosuppression (via immunomodulators), achieving both anti-proliferative and immune-activating effects in a unified therapeutic platform.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent employs composite nanovesicle materials that integrate multiple functional components: chemotherapeutic drugs, immunomodulatory agents, targeting ligands, and stabilizing lipids. This composite structure enables the delivery system to perform multiple functions simultaneously - tumor cell killing, immune activation, and targeted delivery - thereby overcoming the limitation of conventional chemotherapy that fails to address immunosuppression.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12605395B2Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy

Publication Date: 2026.04.21 UNIVERSITY OF CINCINNATI

AI summary

Many tumors induce and maintain an immunosuppressive tumor microenvironment (TME) that enables tumor to escape host immune system. The present disclosure identifies that cancer cells secrete exosome/microparticle-free, soluble, phosphorylated Hsp70 (pHsp70) (Heat Shock Protein 70 (Hsp70))), which triggers macrophage (M) M2 polarization. It is a further aspect that lipid nanovesicles (NVs) made of dioleoylphosphatidylglycerol (DOPG) and of DOPG complexed with saposin C (SapC) bind to cancer secreted Hsp70, inhibit M differentiation and polarization, and reduce tumor growth. In addition, administration of DOPG-NVs rendered monocytes insensitive to TLR2 (Toll Like Receptor 2) and TLR6 (Toll Like Receptor 6) ligands, suggesting that administration of DOPG-NVs interferes with TLR function.